doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...469470471472473474475476477478479...522523»
  • ||||||||||  cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Trial primary completion date, BRCA Biomarker:  Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (clinicaltrials.gov) -  Oct 5, 2017   
    P2,  N=170, Recruiting, 
    Trial primary completion date: Jun 2018 --> Oct 2021
  • ||||||||||  bortezomib / Generic mfg.
    Enrollment closed, Trial primary completion date, Combination therapy:  Modified Bortezomib-based Combination Therapy for Multiple Myeloma (clinicaltrials.gov) -  Oct 5, 2017   
    P4,  N=80, Active, not recruiting, 
    Trial primary completion date: Jun 2018 --> Oct 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Trial initiation date:  Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (clinicaltrials.gov) -  Oct 2, 2017   
    P=N/A,  N=150, Recruiting, 
    The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy. Initiation date: Jan 2016 --> Apr 2015
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Review, Journal:  Olaratumab for the treatment of advanced soft tissue sarcoma. (Pubmed Central) -  Sep 30, 2017   
    We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Multi-drug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. (Pubmed Central) -  Sep 29, 2017   
    CIVO also classified patient-specific tumor resistance to the most effective agent, doxorubicin, and further enabled assessment of a preclinical autophagy inhibitor, PS-1001, to reverse doxorubicin resistance...The ability to evaluate and cross-compare multiple drugs and drug combinations simultaneously in living tumors and across a diverse immune-competent patient population may provide a foundation from which to make informed drug development decisions. This method also represents a viable functional approach to complement current precision oncology strategies.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
    Trial primary completion date:  Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov) -  Sep 27, 2017   
    P2,  N=60, Active, not recruiting, 
    The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma. Trial primary completion date: Sep 2017 --> Sep 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. (Pubmed Central) -  Sep 27, 2017   
    Here we demonstrated that doxorubicin (DOX) treatment of 4T1 breast tumor-bearing mice led to the induction of IL-13R(+)miR-126a(+) MDSCs (DOX-MDSC)...We also showed that MDSC miR-126a rescues DOX-induced MDSC death in a S100A8/A9-dependent manner and promotes tumor angiogenesis. Our findings provide insight into the MDSC exosomal-mediated chemoresistance mechanism, which will be useful for the design of inhibitors targeting the blocking of induction of miR-126a(+) MDSCs.Oncogene advance online publication, 27 June 2016; doi:10.1038/onc.2016.229.
  • ||||||||||  carboplatin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Biomarker, Journal:  Metabolic interrogation as a tool to optimize chemotherapeutic regimens. (Pubmed Central) -  Sep 22, 2017   
    Lactate interrogation also predicted doxorubicin effects on cell death in both solid tumor (HNSCC) and acute myelogenous leukemia (AML) cell lines.Real-time metabolic interrogation of acute changes in cell and tumor lactate levels reflects chemotherapy effects on DNA damage, cell death and tumor growth delay. We have identified a real-time biomarker of chemotherapy effectiveness which can be used to develop adaptive, iterative and personalized treatment regimens against a variety of solid and hematopoietic malignancies.
  • ||||||||||  ibrutinib / Generic mfg.
    Journal:  Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. (Pubmed Central) -  Sep 22, 2017   
    In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker:  Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) -  Sep 21, 2017   
    P2,  N=6, Active, not recruiting, 
    The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be recommended in this setting. Recruiting --> Active, not recruiting | N=26 --> 6 | Trial primary completion date: Apr 2019 --> Mar 2017
  • ||||||||||  letrozole / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. (Pubmed Central) -  Sep 18, 2017   
    She received adjuvant radiation therapy and initiated letrozole, with excellent compliance during the interval 6-year period...The patient reported mild pain that was adequately controlled with over-the-counter anti-inflammatory medications. She has remained active with an excellent performance status.
  • ||||||||||  Trial primary completion date, Metastases:  High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (clinicaltrials.gov) -  Sep 14, 2017   
    P3,  N=86, Recruiting, 
    This treatment approach including standardized 3-drug preoperative chemotherapy, surgical resection within 12 weeks of diagnosis and response and histology-based postoperative therapy improved EFS and OS and preservation of renal parenchyma compared with historical outcomes for children with BWT. Trial primary completion date: Jul 2017 --> Jul 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., decitabine / Generic mfg.
    Journal:  Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. (Pubmed Central) -  Sep 14, 2017   
    To overcome these barriers, we reprogrammed tumor-immune cell cross-talk by combined use of decitabine and adoptive immunotherapy, containing tumor-sensitized T cells and CD25(+) NKT cells...We used Adriamycin chemotherapy or radiation therapy, which simultaneously induce tumor cell death and tumor dormancy...Our results suggest that immunotherapy could be highly effective against quiescent dormant tumor cells. The challenge is to develop combinatorial therapies that could establish a quiescent type of tumor dormancy, which would be the best target for immunotherapy.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Trial withdrawal:  Doxorubicin Pharmacokinetic (PK) Study (clinicaltrials.gov) -  Sep 11, 2017   
    P1/2,  N=0, Withdrawn, 
    Initiation date: Aug 2017 --> Dec 2017 Terminated --> Withdrawn
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). (Pubmed Central) -  Sep 10, 2017   
    Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer...National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab...Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative. Conclusion The TaxAC regimens improved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared with the TC6 regimen.
  • ||||||||||  ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. (Pubmed Central) -  Sep 9, 2017   
    Patients were treated with multimodal treatment approaches including primary surgical resection, neoadjuvant and/or adjuvant chemotherapy, and liver transplantation resulting in overall survival reported between 20% and 100% with significant improvement over the recent years. We show that complete tumor removal remains the key element of treatment and our single-institutional experience and data in the published literature suggest that combination chemotherapy with ifosfamide and doxorubicin to facilitate complete surgical resection is an effective approach to cure children with UESL.